Clinical comparison · GLP-1 / weight loss
Semaglutide vs Tirzepatide
Semaglutide is the entry-level GLP-1 with a longer clinical history and lower cost. Tirzepatide is the dual GIP/GLP-1 successor with superior weight-loss outcomes in head-to-head trials.
Attribute
Semaglutide
Tirzepatide
Mechanism
GLP-1 receptor agonist. Delays gastric emptying, boosts satiety, augments insulin secretion.
Dual GIP/GLP-1 receptor agonist. Additive satiety, insulin secretion, and glucagon suppression.
Standard dosing
0.25 mg weekly, titrated q4 weeks to a 1.7–2.4 mg maintenance dose.
2.5 mg weekly, titrated q4 weeks up to 15 mg maintenance.
Indications
- Medical weight loss
- Metabolic syndrome adjunct
- Type 2 diabetes (branded)
- Medical weight loss
- Type 2 diabetes (branded)
- Metabolic syndrome
Strengths
- Long clinical history
- Simpler side-effect profile at low doses
- Lower cost per week
- Superior weight-loss outcomes vs semaglutide in trials
- Broader dose range for tolerance-matching
Cautions
- Slower weight-loss curve than tirzepatide
- GI side effects during titration
- MTC / MEN2 contraindication
- More expensive
- Same MTC / pancreatitis contraindications
- Gallbladder monitoring
Choose Semaglutide when
Patient is new to GLP-1s, budget-sensitive, or has a modest weight-loss goal.
Wholesale Semaglutide →Choose Tirzepatide when
Patient plateaued on semaglutide, has a larger target weight loss, or wants the strongest available option.
Wholesale Tirzepatide →FAQs
- Is tirzepatide better than semaglutide?
- In head-to-head trials tirzepatide produces greater weight loss on average. Semaglutide remains a strong first-line for tolerance and cost.
- Can a patient switch from semaglutide to tirzepatide?
- Yes. Discontinue semaglutide, wait one dosing interval, then start tirzepatide at 2.5 mg weekly. Do not dose-match across agents.
- Do both share the same contraindications?
- Yes. Personal or family history of MTC, MEN2, prior pancreatitis, and pregnancy are contraindicated for both.